Zentalis Pharmaceuticals Inc (NAS:ZNTL)
$ 11.65 0.21 (1.84%) Market Cap: 827.30 Mil Enterprise Value: 366.02 Mil PE Ratio: 0 PB Ratio: 1.80 GF Score: 36/100

Zentalis Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2023 / 02:10PM GMT
Release Date Price: $24.25 (-1.82%)
Michael Eric Ulz
Morgan Stanley, Research Division - Equity Analyst

Good morning, everyone. Thanks for joining us on day 3 of the Morgan Stanley Global Healthcare Conference. I'm Mike Ulz, for the biotech analyst here, and it's my pleasure to introduce Kim Blackwell, CEO of Zentalis Pharmaceuticals. Just a reminder for today, the format is a fireside chat. But before we get started, I just need to read a quick disclosure statement. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

And with that, Ken, thanks for joining us today. And maybe I can just turn it over to you for some brief background on Zentalis, and then we can get into some Q&A.

Kimberly Lynn Blackwell
Zentalis Pharmaceuticals, Inc. - CEO & Director

Sure. Well, thanks for having me. For those of you who are brand new to the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot